MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor

Casandra

Casandra Test Code MC98143Version 1 (DRAFT)

Performing Lab

Lab Mayo Clinic LabLab Test ID MCOCPCPT Codes 81457, 88381

MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor

Clinical Use

Use

This test is primarily used to determine if patients with ovarian, fallopian tube, and peritoneal cancer will respond to targeted therapy. It assesses the microsatellite instability (MSI) which is crucial for immunotherapy decisions. The test evaluates somatic mutations within a curated list of DNA damage response genes, including ATM, ATR, BARD1, BRCA1, BRCA2, BRIP1, CDK12, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, and RAD51D. This information is useful for assessing prognosis, guiding treatment, and potentially determining eligibility for clinical trials.

Special Instructions

Not provided.

Limitations

This test cannot differentiate between somatic and germline alterations, and further testing may be required if there is a potential hereditary risk. It does not detect multi-exon deletions, duplications, larger-scale genomic variants, or epigenetic modifications. The sensitivity of the assay is limited to detecting variants with at least a 5% mutant allele frequency. Variants observed in PMS2 exons 11-15 may originate from either PMS2 or its pseudogene PMS2CL, requiring additional testing for clarity.

Test Details

New York Approved